
After helping build the first commercial chapter of 3D bioprinting, the chemical engineer returned to the stubborn question underneath it all: can a small piece of human tissue make a better decision than a celebrated animal model?
Drug development still asks mice to predict people. Viscient’s nine-person team is building human liver disease in a dish - then using it to decide which medicines deserve a clinical trial.